SK Bioscience reports positive results from phase 1, 2 clinical trials
TechnologyNov 5, 2021
SK Bioscience announced Friday positive results from phase 1 and 2 clinical studies of its COVID-19 vaccine candidate GBP510, increasing the prospect of Korea’s first homegrown coronavirus vaccine debuting next year. The Korean firm said people who received the vaccine candidate had neutralizing antibodies at levels 3-6 times higher than those of people who recovered from COVID-19. No severe side effects were reported during the clinical studies, it added. The phase 1 and 2 clinical